The Role of Cytokines in Cutaneous T Cell Lymphoma: A Focus on the State of the Art and Possible Therapeutic Targets
- PMID: 38607023
- PMCID: PMC11012008
- DOI: 10.3390/cells13070584
The Role of Cytokines in Cutaneous T Cell Lymphoma: A Focus on the State of the Art and Possible Therapeutic Targets
Abstract
Cutaneous T cell lymphomas (CTCLs), encompassing mycosis fungoides (MF) and Sézary syndrome (SS), present a complex landscape influenced by cytokines and cellular responses. In this work, the intricate relationship between these inflammatory proteins and disease pathogenesis is examined, focusing on what is known at the clinical and therapeutic levels regarding the most well-known inflammatory mediators. An in-depth look is given to their possible alterations caused by novel immunomodulatory drugs and how they may alter disease progression. From this narrative review of the actual scientific landscape, Interferon-gamma (IFN-γ) emerges as a central player, demonstrating a dual role in both promoting and inhibiting cancer immunity, but the work navigates through all the major interleukins known in inflammatory environments. Immunotherapeutic perspectives are elucidated, highlighting the crucial role of the cutaneous microenvironment in shaping dysfunctional cell trafficking, antitumor immunity, and angiogenesis in MF, showcasing advancements in understanding and targeting the immune phenotype in CTCL. In summary, this manuscript aims to comprehensively explore the multifaceted aspects of CTCL, from the immunopathogenesis and cytokine dynamics centred around TNF-α and IFN-γ to evolving therapeutic modalities. Including all the major known and studied cytokines in this analysis broadens our understanding of the intricate interplay influencing CTCL, paving the way for improved management of this complex lymphoma.
Keywords: CTCL; chemokine; cutaneous; inflammatory; lymphoma; mediators; oncology; protein; skin.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.J Am Acad Dermatol. 2014 Feb;70(2):205.e1-16; quiz 221-2. doi: 10.1016/j.jaad.2013.07.049. J Am Acad Dermatol. 2014. PMID: 24438969 Review.
-
New Molecular and Biological Markers in Cutaneous T Cell Lymphoma: Therapeutic Implications.Curr Hematol Malig Rep. 2023 Jun;18(3):83-88. doi: 10.1007/s11899-023-00692-w. Epub 2023 Apr 5. Curr Hematol Malig Rep. 2023. PMID: 37017872 Review.
-
The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Pathways and targets for immune restoration and tumor eradication.J Am Acad Dermatol. 2021 Mar;84(3):587-595. doi: 10.1016/j.jaad.2020.12.027. Epub 2020 Dec 22. J Am Acad Dermatol. 2021. PMID: 33352267 Free PMC article. Review.
-
The Microenvironment's Role in Mycosis Fungoides and Sézary Syndrome: From Progression to Therapeutic Implications.Cells. 2021 Oct 17;10(10):2780. doi: 10.3390/cells10102780. Cells. 2021. PMID: 34685762 Free PMC article. Review.
-
Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.J Am Acad Dermatol. 2014 Feb;70(2):223.e1-17; quiz 240-2. doi: 10.1016/j.jaad.2013.08.033. J Am Acad Dermatol. 2014. PMID: 24438970 Review.
Cited by
-
OX40-OX40L Axis in Cutaneous T-Cell Lymphomas: Pathogenic, Prognostic, and Potential Therapeutic Perspectives.Biomolecules. 2025 May 13;15(5):715. doi: 10.3390/biom15050715. Biomolecules. 2025. PMID: 40427608 Free PMC article. Review.
-
Cutaneous T-Cell Lymphoma: Yin-Yang Effects of Transcription Factors HLF and NFIL3 in Regulation of Malignant T-Cell Markers in the Context of HDAC Inhibitor Romidepsin Treatment.Cancers (Basel). 2025 Jul 17;17(14):2380. doi: 10.3390/cancers17142380. Cancers (Basel). 2025. PMID: 40723261 Free PMC article.
-
A Narrative Review of the State of the Art of CCR4-Based Therapies in Cutaneous T-Cell Lymphomas: Focus on Mogamulizumab and Future Treatments.Antibodies (Basel). 2024 Apr 22;13(2):32. doi: 10.3390/antib13020032. Antibodies (Basel). 2024. PMID: 38804300 Free PMC article. Review.
-
Aptamin C enhances anti-cancer activity NK cells through the activation of STAT3: a comparative study with vitamin C.Anat Cell Biol. 2024 Sep 30;57(3):408-418. doi: 10.5115/acb.24.120. Epub 2024 Jul 25. Anat Cell Biol. 2024. PMID: 39048513 Free PMC article.
-
Dermatoscopic Patterns in Mycosis Fungoides: Observations from a Case-Series Retrospective Analysis and a Review of the Literature.Diagnostics (Basel). 2025 Apr 29;15(9):1136. doi: 10.3390/diagnostics15091136. Diagnostics (Basel). 2025. PMID: 40361954 Free PMC article.
References
-
- Dobos G., de Masson A., Ram-Wolff C., Beylot-Barry M., Pham-Ledard A., Ortonne N., Ingen-Housz-Oro S., Battistella M., d’Incan M., Rouanet J., et al. Epidemiological changes in cutaneous lymphomas: An analysis of 8593 patients from the French Cutaneous Lymphoma Registry. Br. J. Dermatol. 2021;184:1059–1067. doi: 10.1111/bjd.19644. - DOI - PubMed
-
- Pileri A., Morsia E., Zengarini C., Torre E., Goteri G., Quaglino P., Pimpinelli N., Paulli M., A Pileri S., Zinzani P.L., et al. Epidemiology of cutaneous T-cell lymphomas: State of the art and a focus on the Italian Marche region. Eur. J. Dermatol. 2023;33:360–367. doi: 10.1684/ejd.2023.4531. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical